Table 3.
Correlates of overall survival – 5-month landmark (without and with type of first HCC treatment)
| Overall survival (Without first HCC treatment) n=6644 HR (95% CI) | Overall survival (with first HCC treatment) n=6644 HR (95% CI) | |
|---|---|---|
| Delayed treatment | 1.15 (1.05,1.25) | 1.07 (0.98,1.17) |
| Age at diagnosis | ||
| 65 – 69 years | Ref | Ref |
| 70 – 74 years | 1.15 (1.06,1.24) | 1.16 (1.07,1.25) |
| 75 – 79 years | 1.31 (1.21,1.41) | 1.25 (1.16,1.36) |
| 80 years and older | 1.44 (1.33,1.57) | 1.36 (1.25,1.48) |
| Male | 1.13 (1.06,1.20) | 1.10 (1.04,1.18) |
| Race and ethnicity | ||
| White | Ref | Ref |
| Black | 0.84 (0.63,1.11) | 0.79 (0.58,1.07) |
| Asian | 0.83 (0.73,0.93) | 0.79 (0.69,0.90) |
| Hispanic | 1.40 (1.08,1.82) | 1.32 (1.03,1.69) |
| Other/Unknown | 0.75 (0.64,0.89) | 0.78 (0.66,0.92) |
| Neighborhood-level SES | ||
| Low poverty neighborhoods | Ref | Ref |
| Moderate poverty neighborhoods | 1.04 (0.96,1.12) | 1.02 (0.94,1.10) |
| High poverty neighborhoods | 1.07 (0.97,1.18) | 1.02 (0.92,1.13) |
| Interaction of race, ethnicity, and poverty | ||
| Black#Moderate poverty neighborhoods | 1.17 (0.83,1.64) | 1.19 (0.83,1.70) |
| Black#High poverty neighborhoods | 1.33 (0.96,1.84) | 1.31 (0.93,1.86) |
| Asian#Moderate poverty neighborhoods | 0.99 (0.83,1.19) | 1.05 (0.87,1.27) |
| Asian#High poverty neighborhoods | 0.93 (0.75,1.16) | 0.97 (0.77,1.23) |
| Hispanic#Moderate poverty neighborhoods | 0.94 (0.67,1.32) | 0.96 (0.69,1.33) |
| Hispanic#High poverty neighborhoods | 0.72 (0.51,1.01) | 0.72 (0.52,1.01) |
| Geographic region | ||
| West | Ref | Ref |
| Northeast | 0.94 (0.87,1.01) | 0.97 (0.90,1.05) |
| Midwest | 1.10 (0.99,1.22) | 1.12 (1.01,1.25) |
| South | 1.08 (0.99,1.18) | 1.16 (1.06,1.27) |
| Metropolitan status | ||
| Metro > 1 million | Ref | Ref |
| Metro 250,000 – 1 million | 1.03 (0.96,1.11) | 1.03 (0.96,1.10) |
| Metro <250,000 | 1.02 (0.91,1.15) | 0.99 (0.87,1.11) |
| Non-Metro | 0.92 (0.83,1.03) | 0.93 (0.83,1.04) |
| Tumor Staging | ||
| Unifocal <=5 cm without vascular invasion and metastasis | Ref | Ref |
| Beyond unifocal without vascular invasion and metastasis | 1.58 (1.47,1.69) | 1.46 (1.36,1.57) |
| Vascular invasion or metastasis | 2.16 (1.87,2.49) | 2.15 (1.84,2.52) |
| Non-determinable | 1.96 (1.80,2.14) | 1.83 (1.68,2.00) |
| NCI comorbidity index | ||
| 0 | Ref | Ref |
| 1 | 1.04 (0.95,1.13) | 1.04 (0.95,1.14) |
| 2 | 1.02 (0.93,1.12) | 1.03 (0.93,1.13) |
| 3 | 1.07 (0.97,1.17) | 1.08 (0.98,1.19) |
| 4 | 1.20 (1.06,1.36) | 1.14 (0.99,1.31) |
| >=5 | 1.27 (1.14,1.42) | 1.22 (1.09,1.37) |
| Liver disease etiology | ||
| HCV | Ref | Ref |
| HBV | 0.68 (0.60,0.78) | 0.72 (0.62,0.82) |
| Alcohol related liver disease | 1.06 (0.96,1.18) | 1.05 (0.95,1.16) |
| Other liver diseases | 0.90 (0.74,1.10) | 0.96 (0.79,1.17) |
| MAFLD | 1.01 (0.93,1.08) | 1.04 (0.97,1.12) |
| No identifiable liver disease | 1.06 (0.96,1.17) | 1.12 (1.01,1.24) |
| Liver dysfunction | ||
| Presence of hepatic encephalopathy | 1.06 (0.93,1.21) | 1.08 (0.95,1.23) |
| Presence of ascites | 1.15 (1.04,1.27) | 1.07 (0.96,1.18) |
| First HCC treatment type | ||
| Liver transplantation | 0.33 (0.26,0.43) | |
| Surgical resection | 0.49 (0.45,0.53) | |
| Local ablation | 0.82 (0.76,0.89) | |
| Embolization | Ref | |
| Systemic chemotherapy | 1.56 (1.44,1.69) | |
| Radiation | 1.56 (1.34,1.82) |